Biologics News
Designing Patient Hubs Purpose-Built for Cell and Gene Therapies
This Pharmaceutical Commerce article explores how purpose‑built patient hubs can streamline access, reduce barriers and better support the complex needs of cell and gene therapy patients. It was co‑authored by Ela Lourido, vice president and general manager of Biologics by McKesson, and Joe DePinto, head of cell, gene and advanced therapies for InspiroGene by McKesson.
How Proactive Specialty Pharmacy Care Helps Prevent Medication Waste
Read about how Biologics by McKesson uses proactive pharmacy care and personalized support to help patients stay on therapies, reduce costs and improve outcomes.
ZYCUBO® (copper histidinate), First FDA-Approved Treatment for Patients with Menkes Disease, Exclusively Available at Biologics by McKesson in the United States
Cary, N.C. , Jan. 13, 2026 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
Biologics by McKesson’s Pharmacy Elite™ Selected as Hub for Rigel Pharmaceuticals’ Tavalisse®, Gavreto® and Rezlidhia®
Cary, N.C. , Jan. 2, 2026 – Biologics by McKesson’s Pharmacy Elite™, has been awarded the Rigel Pharmaceuticals Hub contract
AQVESME® (mitapivat), FDA-Approved for Adults with Thalassemia, Exclusively Available at Biologics by McKesson
Cary, N.C. , Dec. 29, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene,
The Future of Oncology is Personal, and It’s Already Here
Learn how McKesson connects biopharma, providers and patients to deliver precision oncology at scale through integrated logistics, specialty pharmacy and high‑touch support.